Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study

Blood

Volumn 118, Issue 25, 2011, Pages 6515-6520

  Frederiksen, Henrik ^a,b   Farkas, Dóra Körmendiné ^a   Christiansen, Christian Fynbo ^a   Hasselbalch, Hans Carl ^c   Sørensen, Henrik Toft ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGUS CANCER; EYE CANCER; FEMALE; HEALTH CARE SYSTEM; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OROPHARYNX CANCER; PANCREAS CANCER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSTATE CANCER; SKIN CANCER; THROMBOCYTHEMIA; URINARY TRACT CANCER;

EID: 84055218968     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-348755     Document Type: Article

References (31)

1. Swerdlow S, Campo E, Harris NL, eds.; International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008.
2. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905-914. (Pubitemid 351698623)
3. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232. (Pubitemid 46218714)
4. Dameshek W. Physiopathology and course of polycythemia vera as related to therapy. J Am Med Assoc. 1950;142(11):790-797.
5. Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2068-2073.
6. Rebora P, Czene K, Antolini L, Passerini CG, Reilly M, Valsecchi MG. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol. 2010;172(9):1028-1033.
7. Fallah M, Kharazmi E, Sundquist J, Hemminki K. Higher risk of primary cancers after polycythaemia vera and vice versa [published online ahead of print]. Br J Haematol. doi:10.1111/j.1365-2141.2010.08538.
8. Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287(5462):2398-2399. (Pubitemid 30185417)
9. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268. (Pubitemid 29299976)
10. Nørgaard M, Skriver MV, Gregersen H, Pedersen G, Schonheyder HC, Sorensen HT. The data quality of haematological malignancy ICD-10 diagnoses in a population-based hospital discharge registry. Eur J Cancer Prev. 2005;14(3):201-206. (Pubitemid 40780442)
11. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull. 1997;44(5):535-539.
12. Breslow NE, Day NE. Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ. 1987;82:1-406.
13. Christensen S, Thomsen RW, Torring ML, Riis A, Norgaard M, Sorensen HT. Impact of COPD on outcome among patients with complicated peptic ulcer. Chest. 2008;133(6):1360-1366. (Pubitemid 351892991)
14. Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115(14):2882-2890.
15. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670. (Pubitemid 40446255)
16. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304(8):441-447. (Pubitemid 11178999)
17. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110(3):577-583.
18. Radaelli F, Onida F, Rossi FG, et al. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology. 2008;13(4):195-202.
19. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89(7):2319-2327. (Pubitemid 27143278)
20. Haanen C, Mathé G, Hayat M. Treament of polycythemia vera by radiophosphorus or busulphan: A randomized trial. Br J Cancer. 1981;44:75-80. (Pubitemid 11078389)
21. Najean Y. Association of renal carcinoma and polycythemia vera: 5 cases in which nephrectomy preceded and did not influence the clinical course of the polycythemia. Nouv Rev Fr Hematol. 1991;33(1):9-10.
22. Sanchez-Palacios C, Guitart J. Hydroxyurea-associated squamous dysplasia. J Am Acad Dermatol. 2004;51(2):293-300.
23. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850-858. (Pubitemid 28280552)
24. Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93(12):1792-1796.
25. Ljungberg B. Prognostic markers in renal cell carcinoma. Curr Opin Urol. 2007;17(5):303-308. (Pubitemid 47344615)
26. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-3184.
27. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741-1750.
28. Sørensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst. 2004;96(9):709-711. (Pubitemid 38660234)
29. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009;125(8):1747-1754.
30. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-1061.
31. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. (Pubitemid 36302244)